Vfend Use In Febrile Neutropenia Should Be Limited To High-Risk Patients

Pfizer's Vfend indication for empirical antifungal therapy in febrile neutropenia could be limited to high-risk patients, the Antiviral Drugs Advisory Committee suggested to FDA in an Oct. 4 meeting.